<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499159</url>
  </required_header>
  <id_info>
    <org_study_id>14-1656</org_study_id>
    <nct_id>NCT02499159</nct_id>
  </id_info>
  <brief_title>Pain Management in Response to Exparel vs. Standard Bupivicaine</brief_title>
  <acronym>VATS Exparel</acronym>
  <official_title>A Randomized Controlled Trial of the Effectiveness of Liposomal Bupivacaine (Exparel) When Compared to Local Injection of Bupivacaine After Thoracoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mednax National Medical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on
      decreasing the amount of consumed pain medications.

      Patients will be randomly selected to received either Exparel or standard bupivicaine
      injection during surgery. Patients will be followed up to assess pain levels using a visual
      pain scale, and to assess how much pain medication was consumed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exparel is a formulation of liposomal bupivacaine that is reported to allow local anesthesia
      for up to 72 hours post injection.

      It is the investigators' aim to follow their prior study with a randomized trial to compare
      local infiltration of liposomal bupivacaine at the conclusion of each procedure with
      injections of standard .25% bupivacaine.

      Patients in group A will receive, at the end of the surgical procedure, injections of
      liposomal bupivacaine (Exparel) (266 mg, 20 mL, diluted at surgeon's discretion) into the
      thoracoscopic port incision sites and around the intercostal nerves serving that space.

      Patients in group B will receive, at the end of the surgical procedure, injections of
      standard .25% bupivacaine into the thoracoscopic port incision sites and around the
      intercostal nerves serving that space.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Amounts of Pain Medications Consumed Through Post-operative Day 7</measure>
    <time_frame>Assessed daily for 7 days post-procedure</time_frame>
    <description>Using questionnaires, patients are asked if they took Dilaudid, Tylenol, Motrin, or other opioids and if so, how many tablets.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analog Pain Scores (7 Days)</measure>
    <time_frame>Assessed at day 7 post-procedure</time_frame>
    <description>Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analog Pain Scores (30 Days)</measure>
    <time_frame>Assessed at 30 days post-procedure</time_frame>
    <description>Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Paresthesias (7 Days)</measure>
    <time_frame>Assessed at day 7 post-procedure</time_frame>
    <description>Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves since the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Paresthesias (30 Days)</measure>
    <time_frame>Assessed at day 30 post-procedure</time_frame>
    <description>Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>From end of procedure until discharge, usually 0-2 days.</time_frame>
    <description>Median length of stay in days until discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to Baseline Activity</measure>
    <time_frame>Assessed at 30 days post-procedure</time_frame>
    <description>Using surveys, patients are asked if they have been able to return to baseline activity levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to Work</measure>
    <time_frame>Assessed at 30 days post-procedure</time_frame>
    <description>Using surveys, patients are asked if they have been able to return to work.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Until Return to Work</measure>
    <time_frame>Assessed at 30 days post-procedure</time_frame>
    <description>Using surveys, the number of days to return to work was assessed for patients who were able to return to work.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Hospital Cost</measure>
    <time_frame>Total cost assessed from patient registration until discharge to home (usually 0-2 days).</time_frame>
    <description>Overall hospital cost of patient procedure and stay will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Exparel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon's discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25% standard bupivicaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivicaine</intervention_name>
    <description>266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.</description>
    <arm_group_label>Exparel</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25% standard bupivicaine</intervention_name>
    <description>standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
    <arm_group_label>0.25% standard bupivicaine</arm_group_label>
    <other_name>Bupivicaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients over 18 years of age

          -  Isolated thoracoscopic procedure for therapeutic or diagnostic purposes

        Exclusion Criteria:

          -  Previous ipsilateral thoracic surgery

          -  Need for operative pleurectomy or pleurodesis

          -  Chronic use of pain medication -narcotics or nonsteroidal antiinflammatory drugs
             (NSAIDs), sedatives, or hypnotics

          -  Allergies to bupivacaine or other local anesthetics, narcotics, NSAIDs or
             acetaminophen

          -  Liver dysfunction (INR &gt; 1.5, albumin &lt; 2.8g/dl, bilirubin &gt; 2mg/dl)

          -  Renal dysfunction (eGFR &lt; 60ml/min/1.73m2)

          -  History of peptic ulcerative disease

          -  Severe chronic obstructive pulmonary disease (COPD) requiring continuous oxygen
             supplementation

          -  Inability to consent

          -  Pregnancy

          -  Need for conversion from a Video-Assisted Thoracic Surgery procedure to a thoracotomy

          -  Patient is discharged from the hospital with a chest tube in place

          -  Patient fails to comply with post-operative instructions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandeep J Khandhar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiac, Vascular, and Thoracic Surgery Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiac, Vascular, and Thoracic Surgery Associates</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Whitson BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg. 2008 Dec;86(6):2008-16; discussion 2016-8. doi: 10.1016/j.athoracsur.2008.07.009. Review.</citation>
    <PMID>19022040</PMID>
  </results_reference>
  <results_reference>
    <citation>Allen MS, Halgren L, Nichols FC 3rd, Cassivi SD, Harmsen WS, Wigle DA, Shen KR, Deschamps C. A randomized controlled trial of bupivacaine through intracostal catheters for pain management after thoracotomy. Ann Thorac Surg. 2009 Sep;88(3):903-10. doi: 10.1016/j.athoracsur.2009.04.139.</citation>
    <PMID>19699918</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan VW, Chung F, Cheng DC, Seyone C, Chung A, Kirby TJ. Analgesic and pulmonary effects of continuous intercostal nerve block following thoracotomy. Can J Anaesth. 1991 Sep;38(6):733-9.</citation>
    <PMID>1914056</PMID>
  </results_reference>
  <results_reference>
    <citation>Debreceni G, Molnár Z, Szélig L, Molnár TF. Continuous epidural or intercostal analgesia following thoracotomy: a prospective randomized double-blind clinical trial. Acta Anaesthesiol Scand. 2003 Oct;47(9):1091-5.</citation>
    <PMID>12969101</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaiser AM, Zollinger A, De Lorenzi D, Largiadèr F, Weder W. Prospective, randomized comparison of extrapleural versus epidural analgesia for postthoracotomy pain. Ann Thorac Surg. 1998 Aug;66(2):367-72.</citation>
    <PMID>9725371</PMID>
  </results_reference>
  <results_reference>
    <citation>American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2004 Jun;100(6):1573-81.</citation>
    <PMID>15166580</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <results_first_submitted>August 13, 2019</results_first_submitted>
  <results_first_submitted_qc>August 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exparel</keyword>
  <keyword>Thoracoscopy</keyword>
  <keyword>Bupivicaine</keyword>
  <keyword>Liposomal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02499159/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exparel</title>
          <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
        </group>
        <group group_id="P2">
          <title>0.25% Standard Bupivicaine</title>
          <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>30-Day Follow-Up Phone Call</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal due to ineligibility</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two patients who were enrolled were not randomized due to screen failing after consent. These two patients are not included in the baseline population.</population>
      <group_list>
        <group group_id="B1">
          <title>Exparel</title>
          <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
        </group>
        <group group_id="B2">
          <title>0.25% Standard Bupivicaine</title>
          <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="10.9"/>
                    <measurement group_id="B2" value="65" spread="10.8"/>
                    <measurement group_id="B3" value="64" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Amounts of Pain Medications Consumed Through Post-operative Day 7</title>
        <description>Using questionnaires, patients are asked if they took Dilaudid, Tylenol, Motrin, or other opioids and if so, how many tablets.</description>
        <time_frame>Assessed daily for 7 days post-procedure</time_frame>
        <population>4 participants from the Exparel group and 6 participants from the standard group did not return a questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Amounts of Pain Medications Consumed Through Post-operative Day 7</title>
          <description>Using questionnaires, patients are asked if they took Dilaudid, Tylenol, Motrin, or other opioids and if so, how many tablets.</description>
          <population>4 participants from the Exparel group and 6 participants from the standard group did not return a questionnaire.</population>
          <units>tablets</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1294"/>
                    <measurement group_id="O2" value="1455.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analog Pain Scores (7 Days)</title>
        <description>Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.</description>
        <time_frame>Assessed at day 7 post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Analog Pain Scores (7 Days)</title>
          <description>Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.</description>
          <units>score on a scale from 0-10</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analog Pain Scores (30 Days)</title>
        <description>Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.</description>
        <time_frame>Assessed at 30 days post-procedure</time_frame>
        <population>42 subjects in the Exparel group and 47 subjects in the standard group completed the 30-day survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Analog Pain Scores (30 Days)</title>
          <description>Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain.</description>
          <population>42 subjects in the Exparel group and 47 subjects in the standard group completed the 30-day survey.</population>
          <units>score on a scale from 0-10</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Paresthesias (7 Days)</title>
        <description>Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves since the procedure.</description>
        <time_frame>Assessed at day 7 post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Paresthesias (7 Days)</title>
          <description>Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves since the procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Paresthesias (30 Days)</title>
        <description>Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves</description>
        <time_frame>Assessed at day 30 post-procedure</time_frame>
        <population>42 subjects in the Exparel group and 47 subjects in the standard group completed the 30-day survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Paresthesias (30 Days)</title>
          <description>Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves</description>
          <population>42 subjects in the Exparel group and 47 subjects in the standard group completed the 30-day survey.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Median length of stay in days until discharge.</description>
        <time_frame>From end of procedure until discharge, usually 0-2 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Median length of stay in days until discharge.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Return to Baseline Activity</title>
        <description>Using surveys, patients are asked if they have been able to return to baseline activity levels.</description>
        <time_frame>Assessed at 30 days post-procedure</time_frame>
        <population>42 subjects in the Exparel group and 47 subjects in the standard group completed the 30 day survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Return to Baseline Activity</title>
          <description>Using surveys, patients are asked if they have been able to return to baseline activity levels.</description>
          <population>42 subjects in the Exparel group and 47 subjects in the standard group completed the 30 day survey.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Return to Work</title>
        <description>Using surveys, patients are asked if they have been able to return to work.</description>
        <time_frame>Assessed at 30 days post-procedure</time_frame>
        <population>42 subjects in the Exparel group and 47 patients in the standard group completed the 30-day survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Return to Work</title>
          <description>Using surveys, patients are asked if they have been able to return to work.</description>
          <population>42 subjects in the Exparel group and 47 patients in the standard group completed the 30-day survey.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Until Return to Work</title>
        <description>Using surveys, the number of days to return to work was assessed for patients who were able to return to work.</description>
        <time_frame>Assessed at 30 days post-procedure</time_frame>
        <population>At the 30-day call, 24 subjects in the Exparel group and 17 subjects in the standard group indicated that they were able to return to work. Number of days were assessed for these subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Until Return to Work</title>
          <description>Using surveys, the number of days to return to work was assessed for patients who were able to return to work.</description>
          <population>At the 30-day call, 24 subjects in the Exparel group and 17 subjects in the standard group indicated that they were able to return to work. Number of days were assessed for these subjects.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Hospital Cost</title>
        <description>Overall hospital cost of patient procedure and stay will be assessed.</description>
        <time_frame>Total cost assessed from patient registration until discharge to home (usually 0-2 days).</time_frame>
        <population>Data on hospital cost was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Exparel</title>
            <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
          </group>
          <group group_id="O2">
            <title>0.25% Standard Bupivicaine</title>
            <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Hospital Cost</title>
          <description>Overall hospital cost of patient procedure and stay will be assessed.</description>
          <population>Data on hospital cost was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From procedure until the 30-day (plus or minus 10 days) post-procedure phone call.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exparel</title>
          <description>Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon’s discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
Liposomal Bupivicaine: 266 mg, 20 mL total, diluted at surgeon’s discretion, delivered by 22 gauge needle.</description>
        </group>
        <group group_id="E2">
          <title>0.25% Standard Bupivicaine</title>
          <description>Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
0.25% standard bupivicaine: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Anxiety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Nose bleeds</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis Fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Brain tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Occipital Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary blockage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Devon Collins</name_or_title>
      <organization>Inova Health System</organization>
      <phone>703-776-4096</phone>
      <email>Devon.Collins@inova.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

